- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04099446
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer
April 6, 2021 updated by: ProgenaBiome
A Non-Interventional Pilot Study to Explore the Skin Microbes in Skin Cancer Including Melanoma and Non-Melanoma
This study seeks to correlate microbial sequencing data from a punch biopsy in patients with skin cancer both melanoma and non-melanoma.
Study Overview
Status
Withdrawn
Intervention / Treatment
Detailed Description
The human Skin microbiome is a complex, interconnected web of microbes, living in a symbiotic relationship with their host.
There are greater than ten times more bacteria on our bodies than there are human cells, all in a delicate and ever-changing balance to maintain a healthy skin microbiome.
When this balance is disrupted, a condition known as dysbiosis, disease can occur.
There is still a debate over whether dysbiosis is a cause of disease or a symptom of it.
Naturally, since the microbiome has such a profound impact on human health, we want to study and learn as much about the microbiome as possible.
By correlating this data with medical records for the patient's skin cancer, connections may begin to be drawn between organisms present in the microbiome of the skin microbiome, and skin cancer.
Much like fingerprints, no microbiome is identical therefore the only chance we have at understanding disease is by looking at the skin microbiome and comparing the microorganisms on a patient with skin cancer biopsy and non-skin cancer biopsy.
Study Type
Observational
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Ventura, California, United States, 93003
- ProgenaBiome
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Probability Sample
Study Population
Adults 18 and older with a diagnosis of skin cancer
Description
Inclusion Criteria:
- Signed informed consent
- 18 years of age or older
- Diagnosis of skin cancer, both melanoma and non-melanoma
- Able/willing to have a skin punch biopsy in a non-cancerous location
Exclusion Criteria:
- Unable/unwilling to sign informed consent
- Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Correlation of Skin Microbiome to Cancer via Relative Abundance Found in Microbiome Sequencing
Time Frame: 1 year
|
Relative abundance of bacterial classes within taxonomic phyla and, more broadly, within their domain will be analyzed by sequencing the skin microbiome in both cancerous and non-cancerous areas.
These data will then be compared to elucidate unique qualities of the microbiome in skin cancer.
|
1 year
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Validation of sequencing methods
Time Frame: 1 year
|
To validate the sequencing methods used to generate microbiome data
|
1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Anticipated)
October 1, 2019
Primary Completion (Anticipated)
October 1, 2020
Study Completion (Anticipated)
December 1, 2020
Study Registration Dates
First Submitted
September 18, 2019
First Submitted That Met QC Criteria
September 19, 2019
First Posted (Actual)
September 23, 2019
Study Record Updates
Last Update Posted (Actual)
April 8, 2021
Last Update Submitted That Met QC Criteria
April 6, 2021
Last Verified
April 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Skin Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neoplasms, Glandular and Epithelial
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Nevi and Melanomas
- Neoplasms, Basal Cell
- Carcinoma
- Melanoma
- Skin Neoplasms
- Carcinoma, Basal Cell
Other Study ID Numbers
- ProgenaBiome-003
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
IPD Plan Description
Only aggregated, deidentified data will be made available to other researchers.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Cancer
-
University of HawaiiVA Palo Alto Health Care SystemCompletedCancer, Other Than Non-melanoma Skin CancerUnited States
-
EnlundCompletedBreast Cancer | Skin Cancer | Colo-rectal CancerSweden
-
McMaster UniversityRecruitingSkin Cancer, Basal Cell Skin Cancer Skin Cancer, Non-Melanoma Skin Cancers - Squamous Cell Carcinoma Patient SatisfactionCanada
-
SciBase ABRecruitingKeratinocyte Skin CancerGermany
-
Rutgers, The State University of New JerseyCompleted
-
University of MichiganBlue Cross Blue Shield of Michigan FoundationCompletedSkin Cancer PreventionUnited States
-
Xoft, Inc.Eminence Clinical Research, Inc.UnknownNonmelanoma Skin CancerUnited States
-
Fox Chase Cancer CenterNational Cancer Institute (NCI)CompletedSkin Cancer PreventionUnited States
-
Assistance Publique - Hôpitaux de ParisRecruitingSkin Cancer, Non-MelanomaFrance
-
Technische Universität DresdenCompletedNon-melanoma Skin CancerGermany
Clinical Trials on Non-interventional
-
Universitätsklinikum Hamburg-EppendorfSandozUnknownPsoriasisDenmark, Spain, Germany, Poland
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI)RecruitingUse of a Screening Tool to Describe HIV-Related Cancer Burden and Patient Characteristics in the AMCHIV Infections | Cancer | HPV-Related Malignancy | Anal Cancer | HIV-Associated Malignant Neoplasm | AIDS Related Lymphoma | AIDS-related Kaposi Sarcoma | AIDS-Related MalignancyUnited States
-
Bristol-Myers SquibbWithdrawnNon-valvular Atrial FibrillationUnited States
-
Papworth Hospital NHS Foundation TrustLifeArcNot yet recruitingNon-cystic Fibrosis BronchiectasisUnited Kingdom
-
Royal Marsden NHS Foundation TrustRecruitingGastric Cancer | Colorectal Cancer | Pancreatic Cancer | Oesophageal Cancer | Hepato-Biliary Carcinoma in Situ NosUnited Kingdom
-
Shanghai Zhongshan HospitalRecruiting
-
Ankara UniversityRecruiting
-
Chinese University of Hong KongJockey Club Centre for Positive AgeingNot yet recruiting
-
Second Affiliated Hospital, School of Medicine,...RecruitingInterictal FDG-PET Hypometabolism PatternsChina